Stichting European Myeloma Network
- Country
- 🇳🇱Netherlands
- Ownership
- Private
- Employees
- -
- Market Cap
- -
Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 302
- Registration Number
- NCT04483739
- Locations
- 🇳🇱
ErasmusMC, Rotterdam, Rotterdam, Netherlands
🇬🇷Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra General Hospital of Athens, Athens, Greece
🇮🇹ASST Spedali Civili di Brescia - Ematologia, Brescia, Italy
Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease
- Conditions
- Interventions
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 41
- Registration Number
- NCT04166565
- Locations
- 🇬🇷
Anticancer Hospital of Thessaloniki, ThessalonÃki, Greece
🇮🇹University of Bologna, Bologna, Italy
🇮🇹Univerity of Turin, Torino, Italy
A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 40
- Registration Number
- NCT04131309
- Locations
- 🇳🇱
UMCU, Utrecht, Netherlands
🇮🇹University Hospital San Matteo, Pavia, Italy
🇫🇷Hopital De Rangueil CHU, Toulouse, France
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
- Conditions
- Interventions
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 401
- Registration Number
- NCT03896737
- Locations
- 🇬🇷
General Hospital of Athens "Alexandra", Athens, Greece
🇨🇿University Hospital Ostrava, Ostrava, Czechia
🇮🇹A.O.U. Maggiore della Carità di Novara, Novara, Italy
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 690
- Registration Number
- NCT03710603
- Locations
- 🇦🇺
Alfred Hospital, Melbourne, Australia
🇩🇰Odense University Hospital, Odense, Denmark
🇫🇷CHRU Hôtel Dieu, Nantes, France
Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone
- Conditions
- Interventions
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 304
- Registration Number
- NCT03180736
- Locations
- 🇮🇹
Ancona, Ancona, Italy
🇮🇹Brescia, Brescia, Italy
🇨🇿Praha 2, Praha, Czechia
Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 36
- Registration Number
- NCT02204241
- Locations
- 🇮🇹
Fondazione EMN Italy Onlus, Torino, Italy
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)
- Conditions
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 57
- Registration Number
- NCT02185820
- Locations
- 🇮🇹
Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Torino, Italy
Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 63
- Registration Number
- NCT02056756
- Locations
- 🇮🇹
Divisione di Ematologia A.O.U. Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi di Ancona, Ancona, Italy
🇮🇹Fondazione EMN Italy Onlus, Torino, TO, Italy
🇩🇪Universitätsklinikum Schleswig-Holstein (UKSH) - Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Kiel, Germany
Maintenance Therapy With Subcutaneous Bortezomib
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 63
- Registration Number
- NCT01913730
- Locations
- 🇮🇹
Irccs Crob, Rionero in Vulture, Potenza, Italy